Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2021

View Archived Issues

Enrollment ongoing in phase I/II study of PVSRIPO

Mersana starts phase I/II umbrella study of XMT-1536 in high-grade serous ovarian cancer

Venadaparib shows safety and preliminary efficacy in first-in-human trial

Novel tau tubulin kinase 1 inhibitors reduce tau phosphorylation in vivo

Vaccinia virus-expressed SARS-CoV-2 spike protein promotes cellular and humoral immunity in mice

Antitumor activity of luxeptinib described in phase Ia/b study in B-cell malignancies

BCMA CAR-T cells engineered with membrane-bound IL-15 show increased in vivo activity

Dose-dependent weight loss seen in first-in-human study of LY-3437943

Model of diastolic dysfunction with preserved ejection fraction developed to test HDAC6 inhibition

Phase I data for CC-90001 in healthy subjects and in participants with hepatic impairment

Roche patents new BRAF inhibitors

Chinese investigators divulge P2X3 receptor antagonists

Shenzhen Jingtai Technology presents Ret inhibitors

Vivavision Biotechnology describes new ROCK2 inhibitors

PTC Therapeutics discloses compounds for familial dysautonomia

SYNB-1934, optimized live bacterial therapeutic for the treatment of phenylketonuria

Bio-ADM, a novel biomarker of congestion in acute dyspnea

Phase II FORCE study of avdoralimab in COVID-19 misses primary endpoints

Phase I/II trial explores Gadeta's gamma delta TCR cell therapy GDT-002 for multiple myeloma

Downregulation of ERBB4 leads to peripartum cardiomyopathy

HUTCHMED initiates phase I study of HMPL-295 in advanced solid tumors

HIV rebound biomarkers give insights into controllers and, unexpectedly, comorbidities

BNC-210 advances into phase IIb trial in PTSD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.